RESUMEN
Epstein-Barr virus (EBV) has evolved exquisite controls over its host cells, human B lymphocytes, not only directing these cells during latency to proliferate and thereby expand the pool of infected cells, but also to survive and thereby persist for the lifetime of the infected individual. Although these activities ensure the virus is successful, they also make the virus oncogenic, particularly when infected people are immunosuppressed. Here we show, strikingly, that one set of EBV's microRNAs (miRNAs) both sustain Burkitt's lymphoma (BL) cells in the absence of other viral oncogenes and promote the transformation of primary B lymphocytes. BL cells were engineered to lose EBV and found to die by apoptosis and could be rescued by constitutively expressing viral miRNAs in them. Two of these EBV miRNAs were found to target caspase 3 to inhibit apoptosis at physiological concentrations.
Asunto(s)
Linfoma de Burkitt/patología , Herpesvirus Humano 4/fisiología , MicroARNs/genética , Interferencia de ARN , Apoptosis , Linfocitos B/enzimología , Linfocitos B/fisiología , Linfocitos B/virología , Secuencia de Bases , Sitios de Unión , Linfoma de Burkitt/metabolismo , Linfoma de Burkitt/virología , Caspasa 3/genética , Caspasa 3/metabolismo , Línea Celular Tumoral , Proliferación Celular , Supervivencia Celular , Antígenos Nucleares del Virus de Epstein-Barr/genética , Regulación Neoplásica de la Expresión Génica , Interacciones Huésped-Patógeno , HumanosRESUMEN
Viral gene vectors often rely on packaging cell lines, which provide the necessary factors in trans for the formation of virus-like particles. Previously, we reported on a first-generation packaging cell line for gene vectors, which are based on the B-lymphotropic Epstein-Barr virus (EBV), a human gamma-herpesvirus. This 293HEK-derived packaging cell line harbors a helper virus genome with a genetic modification that prevents the release of helper virions, but efficiently packages vector plasmids into virus-like particles with transducing capacity for human B cells. Here, we extended this basic approach towards a non-transforming, virus-free packaging cell line, which harbors an EBV helper virus genome with seven genetic alterations. In addition, we constructed a novel gene vector plasmid, which is devoid of a prokaryotic antibiotic resistance gene, and thus more suitable for in vivo applications in human gene therapy. We demonstrate in this paper that EBV-based gene vectors can be efficiently generated with this much-improved packaging cell line to provide helper virus-free gene vector stocks with transducing capacity for established human B-cell lines and primary B cells.
Asunto(s)
Linfocitos B/virología , Ingeniería Genética , Vectores Genéticos/genética , Transducción Genética/métodos , Ensamble de Virus , Línea Celular , ADN Viral/análisis , Citometría de Flujo , Expresión Génica , Proteínas Fluorescentes Verdes/genética , Virus Helper , Herpesvirus Humano 4 , Humanos , Reacción en Cadena de la Polimerasa , Recombinación Genética , Transfección/métodosRESUMEN
The efficient gene transfer of immunostimulatory cytokines into autologous tumor cells or the transfer of tumor-associated antigens into professional antigen-presenting cells is a prerequisite for many immunotherapeutic approaches. In particular with B cells, the efficiency of gene uptake is one of the limiting factors in cell-based vaccine strategies, since normal and malignant human B cells are commonly refractory to transducing gene vectors. Due to its natural tropism for human B cells, Epstein-Barr virus (EBV), a human herpes virus, might be an option, which we wanted to explore. EBV efficiently infects human B cells and establishes a latent infection, while the viral genome is maintained extrachromosomally. Although these characteristics are attractive, EBV is an oncogenic virus. Here, we present a novel EBV-derived vector, which lacks three EBV genes including two viral oncogenes and an essential lytic gene, and encodes granulocyte-macrophage colony-stimulating factor (GM-CSF) as a cytokine of therapeutic interest. We could show that EBV vectors efficiently transduce different B-cell lines, primary resting B cells, and tumor cells of B-cell lineage. Vector-derived GM-CSF was expressed in sufficient amounts to support the maturation of dendritic cells and their presentation of model antigens to cognate T-cell clones in autologous settings and an allogeneic, HLA-matched assay. We conclude that the EBV vector system might offer an option for ex vivo manipulation of B cells and gene therapy of B-cell lymphomas.
Asunto(s)
Linfocitos B/metabolismo , Terapia Genética/métodos , Vectores Genéticos/administración & dosificación , Factor Estimulante de Colonias de Granulocitos/genética , Herpesvirus Humano 4/genética , Linfoma de Células B/terapia , Presentación de Antígeno , Linfocitos B/inmunología , Línea Celular , Células Cultivadas , Células Dendríticas/inmunología , Endocitosis , Citometría de Flujo , Factor Estimulante de Colonias de Granulocitos/análisis , Factor Estimulante de Colonias de Granulocitos/inmunología , Herpesvirus Humano 4/inmunología , Humanos , Activación de Linfocitos , Linfoma de Células B/inmunología , Linfoma de Células B/virología , Transducción Genética/métodosRESUMEN
We describe AMIDA (autoantibody-mediated identification of antigens), a novel target identification technology based on the immunoprecipitation of disease-specific antigens by autologous serum antibodies followed by two-dimensional electrophoretic separation, and their identification via mass spectrometry. Twenty-seven potential carcinoma antigens were identified including proteins of hitherto unknown function. Validation of one of the identified antigens, cytokeratin 8, revealed its de novo expression in hyperplastic tissue, gradual overexpression with increasing malignancy, and ectopic localization on the cell surface. Furthermore, a strong prevalence of CK8-specific antibodies occurred in the serum of cancer patients already at early disease stages. In situ hybridization for one marker of unknown function, KIAA1273/TOB3, demonstrated its strong overexpression in head and neck carcinomas, thus making it a likely tumor antigen candidate. Eventually, AMIDA could foster significant improvements for the diagnosis and therapy of human diseases eliciting a humoral immune response, and allows for the rapid identification of new target molecules.
Asunto(s)
Alergia e Inmunología , Proteómica/métodos , Anticuerpos/química , Formación de Anticuerpos , Antígenos de Neoplasias/química , Carcinoma de Células Escamosas/inmunología , Línea Celular Tumoral , Separación Celular , Electroforesis en Gel Bidimensional , Citometría de Flujo , Humanos , Inmunohistoquímica , Hibridación in Situ , Queratinas/química , Espectrometría de Masas , Microscopía Fluorescente , Pruebas de Precipitina , Células Tumorales CultivadasRESUMEN
The Epstein-Barr virus (EBV) genome has been detected in lymphomas and in tumors of epithelial or mesenchymal origin such as nasopharyngeal carcinoma or leiomyosarcoma. Thus, there is little doubt that EBV can infect cells of numerous lineages in vivo, in contrast to its in vitro infectious spectrum, which appears restricted predominantly to B lymphocytes. We show here that the EBV BALF4 gene product, the glycoprotein gp110, dramatically enhances the ability of EBV to infect human cells. gp110(high) viruses were up to 100 times more efficient than their gp110(low) counterparts in infecting lymphoid or epithelial cells. In addition, gp110(high) viruses infected the carcinoma cell line HeLa and the T cell lymphoma cell line Molt-4, both previously thought to be refractory to EBV infection. Analysis of several virus isolates showed that the amount of BALF4 present within mature virions markedly differed among these strains. In some strains, gp110 was found expressed during lytic replication not only at the nuclear but also at the cellular membrane. Heterologous expression of gp110 during the virus lytic phase neither altered virus concentration nor affected virus binding to cells. It appears that gp110 plays a crucial role after the virus has adhered to its cellular target. gp110 constitutes an important virulence factor that determines infection of non-B cells by EBV. Therefore, the use of gp110(high) viruses will help to determine the range of the target cells of EBV beyond B lymphocytes and provide a useful in vitro model to assess the oncogenic potential of EBV in these cells.
Asunto(s)
Infecciones por Virus de Epstein-Barr/fisiopatología , Herpesvirus Humano 4/fisiología , Proteínas Virales/fisiología , Animales , Linfoma de Burkitt , Callithrix , Línea Celular , Membrana Celular/virología , Células HeLa , Herpesvirus Humano 4/patogenicidad , Humanos , Riñón , Linfocitos , Membrana Nuclear/virología , Transfección , Células Tumorales Cultivadas , Urotelio , Proteínas Virales/genéticaRESUMEN
The oncogenic latent membrane protein 1 (LMP1) of the Epstein-Barr virus recruits tumor necrosis factor-receptor (TNFR)-associated factors (TRAFs), the TNFR-associated death domain protein (TRADD) and JAK3 to induce intracellular signaling pathways. LMP1 serves as the prototype of a TRADD-binding receptor that transforms cells but does not induce apoptosis. Here we show that TRAF6 critically mediates LMP1 signaling to p38 mitogen-activated protein kinase (MAPK) via a MAPK kinase 6-dependent pathway. In addition, NF-kappaB but not c-Jun N-terminal kinase 1 (JNK1) induction by LMP1 involves TRAF6. The PxQxT motif of the LMP1 C-terminal activator region 1 (CTAR1) and tyrosine 384 of CTAR2 together are essential for full p38 MAPK activation and for TRAF6 recruitment to the LMP1 signaling complex. Dominant-negative TRADD blocks p38 MAPK activation by LMP1. The data suggest that entry of TRAF6 into the LMP1 complex is mediated by TRADD and TRAF2. In TRAF6-knockout fibroblasts, significant induction of p38 MAPK by LMP1 is dependent on the ectopic expression of TRAF6. We describe a novel role of TRAF6 as an essential signaling mediator of a transforming oncogene, downstream of TRADD and TRAF2.
Asunto(s)
Proteínas Portadoras/fisiología , Sistema de Señalización de MAP Quinasas/fisiología , Proteínas/fisiología , Proteínas Adaptadoras Transductoras de Señales , Secuencias de Aminoácidos , Proteínas Quinasas Dependientes de Calcio-Calmodulina/metabolismo , Línea Celular , Transformación Celular Viral , Proteínas del Citoesqueleto , Inducción Enzimática/efectos de los fármacos , Fibroblastos/metabolismo , Marcación de Gen , Células HeLa , Herpesvirus Humano 4/fisiología , Humanos , Péptidos y Proteínas de Señalización Intracelular , Riñón , Proteínas con Dominio LIM , MAP Quinasa Quinasa 6 , Sustancias Macromoleculares , Proteínas de la Membrana/metabolismo , Microscopía Fluorescente , Proteína Quinasa 8 Activada por Mitógenos , Proteínas Quinasas Activadas por Mitógenos/biosíntesis , Proteínas Quinasas Activadas por Mitógenos/genética , Proteínas Quinasas Activadas por Mitógenos/fisiología , Modelos Biológicos , FN-kappa B/fisiología , Fosforilación , Procesamiento Proteico-Postraduccional , Proteínas/genética , Relación Estructura-Actividad , Factor 1 Asociado a Receptor de TNF , Factor 2 Asociado a Receptor de TNF , Factor 6 Asociado a Receptor de TNF , Tirosina/química , Proteínas Quinasas p38 Activadas por MitógenosRESUMEN
Epstein-Barr virus (EBV) replicates in its latent phase once per cell cycle in proliferating B cells. The latent origin of DNA replication, oriP, supports replication and stable maintenance of the EBV genome. OriP comprises two essential elements: the dyad symmetry (DS) and the family of repeats (FR), both containing clusters of binding sites for the transactivator EBNA1. The DS element appears to be the functional replicator. It is not yet understood how oriP-dependent replication is integrated into the cell cycle and how EBNA1 acts at the molecular level. Using chromatin immunoprecipitation experiments, we show that the human origin recognition complex (hsORC) binds at or near the DS element. The association of hsORC with oriP depends on the DS element. Deletion of this element not only abolishes hsORC binding but also reduces replication initiation at oriP to background level. Co-immunoprecipitation experiments indicate that EBNA1 is associated with hsORC in vivo. These results indicate that oriP might use the same cellular initiation factors that regulate chromosomal replication, and that EBNA1 may be involved in recruiting hsORC to oriP.
Asunto(s)
Replicación del ADN , ADN Viral/biosíntesis , Proteínas de Unión al ADN/metabolismo , Herpesvirus Humano 4/genética , Origen de Réplica , Latencia del Virus , Replicación Viral , Animales , Linfocitos B , Sitios de Unión , Antígenos Nucleares del Virus de Epstein-Barr/metabolismo , Herpesvirus Humano 4/fisiología , Humanos , Complejo de Reconocimiento del Origen , RatasAsunto(s)
Infecciones por Virus de Epstein-Barr/genética , Perfilación de la Expresión Génica , Regulación Viral de la Expresión Génica , Herpesvirus Humano 4/genética , Linfocitos B , Línea Celular Transformada , Transformación Celular Viral/genética , Humanos , Plásmidos/genética , Transfección/métodosRESUMEN
Epstein-Barr virus (EBV) interacts with its host in three distinct ways in a highly regulated fashion: (i) EBV infects human B lymphocytes and induces proliferation of the infected cells, (ii) it enters into a latent phase in vivo that follows the proliferative phase, and (iii) it can be reactivated giving rise to the production of infectious progeny for reinfection of cells of the same type or transmission of the virus to another individual. In healthy people, these processes take place simultaneously in different anatomical and functional compartments and are linked to each other in a highly dynamic steady-state equilibrium. The development of a genetic system has paved the way for the dissection of those processes at a molecular level that can be studied in vitro, i.e. B-cell immortalization and the lytic cycle leading to production of infectious progeny. Polymerase chain reaction analyses coupled to fluorescent-activated cell sorting has on the other hand allowed a descriptive analysis of the virus-host interaction in peripheral blood cells as well as in tonsillar B cells in vivo. This paper is aimed at compiling our present knowledge on the process of B-cell immortalization in vitro as well as in vivo latency, and attempts to integrate this knowledge into the framework of the viral life cycle in vivo.
Asunto(s)
Linfocitos B/virología , Herpesvirus Humano 4/fisiología , Animales , Herpesvirus Humano 4/genética , Herpesvirus Humano 4/crecimiento & desarrollo , HumanosRESUMEN
The genetic analysis of human herpesvirus 8 (HHV8), also termed Kaposi's sarcoma-associated virus, has been hampered by severe difficulties in producing infectious viral particles and modifying the viral genome. In this article, we report the successful cloning of the HHV8 complete genome onto a prokaryotic F-plasmid replicon which allows the propagation of the recombinant viral DNA in Escherichia coli. The insertion of the F-plasmid into the HHV8 genome interrupts the ORF56 gene, whose expression product-by homology with the Epstein-Barr virus BSLF1 gene--is supposed to be necessary for lytic DNA replication. After introduction of the recombinant HHV8 DNA into 293 cells, early viral antigens are expressed, suggesting that spontaneous lytic replication is initiated. However, completion of the lytic program is prevented by the absence of the ORF56 protein, and a quasi-latent state is established. Upon reintroduction of the ORF56 viral gene, the block is overcome and infectious HHV8 virions are produced. As the recombinant HHV8 genome can be easily modified in E. coli, this experimental system opens the way to an extensive genetic analysis of other HHV8 functions.
Asunto(s)
Herpesvirus Humano 8/genética , Herpesvirus Humano 8/fisiología , Recombinación Genética , Línea Celular , Escherichia coli/genética , Factor F , Genoma Viral , Humanos , Sistemas de Lectura Abierta/genética , Plásmidos/genética , Replicón , Transfección , Proteínas Virales/genética , Proteínas Virales/metabolismo , Virión/metabolismoRESUMEN
The Epstein-Barr virus (EBV) infects humans and the genome of this infectious agent has been detected in several tumour types, ranging from lymphomas to carcinomas. The analysis of the functions of the numerous viral proteins encoded by EBV has been impeded by the large size of the viral genome, which renders the construction of viral mutants difficult. To overcome these limitations, several genetic systems have been developed that allow the modification of the viral genome. Two different approaches, depending on the host cell type in which the viral mutants are generated, have been used in the past. Traditionally, mutants were constructed in EBV infected eukaryotic cells, but more recently, approaches that make use of a recombinant EBV cloned in Escherichia coli have been proposed. The phenotype associated with the inactivation or modification of nearly 20 of the 100 EBV viral genes has been reported in the literature. In most of the reported cases, the EBV latent genes that mediate the ability of EBV to immortalize infected cells were the targets of the genetic analysis, but some virus mutants in which genes involved in DNA lytic replication or infection were disrupted have also been reported. The ability to modify the viral genome also opens the way to the construction of viral strains with medical relevance. A cell line infected by a virus that lacks the EBV packaging sequences can be used as a helper cell line for the encapsidation of EBV based viral vectors. This cell line will allow the evaluation of EBV as a gene transfer system with applications in gene therapy. Finally, genetically modified non-pathogenic strains will provide a basis for the design of an attenuated EBV live vaccine.
Asunto(s)
Terapia Genética , Herpesvirus Humano 4/genética , Escherichia coli/genética , Técnicas de Transferencia de Gen , Vectores Genéticos , Genoma Viral , Fenotipo , Proteínas Virales/fisiologíaRESUMEN
The binding of the viral major glycoprotein BLLF1 (gp350/220) to the CD21 cellular receptor is thought to play an essential role during infection of B lymphocytes by the Epstein-Barr virus (EBV). However, since CD21-negative cells have been reported to be infectible with EBV, additional interactions between viral and cellular molecules seem to be probable. Based on a recombinant genomic EBV plasmid, we deleted the gene that encodes the viral glycoprotein BLLF1. We tested the ability of the viral mutant to infect different lymphoid and epithelial cell lines. Primary human B cells, lymphoid cell lines, and nearly all of the epithelial cell lines that are susceptible to wild-type EBV infection could also be successfully infected with the viral mutant in vitro, although the efficiency of infection with BLLF1-negative virus was clearly lower than the one observed with wild-type EBV. Our studies show that the interaction between BLLF1 and CD21 is not absolutely required for the infection of lymphocytes and epithelial cells, indicating that viral molecules other than BLLF1 can mediate the binding of EBV to its target cells. In this context, our results further suggest the hypothesis that additional cellular molecules, apart from CD21, allow virus entry into these cells.
Asunto(s)
Linfocitos B/virología , Células Epiteliales/virología , Herpesvirus Humano 4/fisiología , Proteínas de la Matriz Viral/metabolismo , Línea Celular , Transformación Celular Viral , Eliminación de Gen , Herpesvirus Humano 4/genética , Humanos , Ligandos , Receptores de Complemento 3d/metabolismo , Proteínas de la Matriz Viral/genética , Virión/fisiología , VirulenciaRESUMEN
Phorbol esters reactivate Epstein-Barr virus (EBV) from latently infected cells via transcriptional activation of the viral immediate-early gene BZLF1. BZLF1 is a member of the extended AP-1 family of transcription factors that binds to specific BZLF1-binding motifs within early EBV promoters and to consensus AP-1 sites. Regulation of BZLF1's activity is achieved at the transcriptional level as well as through post-translational modifications. Recently, we reported that the transcriptional activity of BZLF1 is augmented by TPA [Baumann, M., Mischak, H., Dammeier, S., Kolch, W., Gires, O., Pich, D., Zeidler, R., Delecluse, H. J. & Hammerschmidt, W., (1998) J. Virol. 72, 8105-8114]. The increase of BZLF1's activity depends on a single serine residue (S186) that is phosphorylated by protein kinase C (PKC) in vitro and in vivo after stimulation with 12-O-tetradecanoylphorbol-13-acetate (TPA). Here, we identified RACK1 as a binding partner of BZLF1 in a yeast interaction trap assay. RACK stands for receptor of activated C-kinase and is involved in targeting activated PKCs and other signaling proteins. In vivo, RACK1 binds directly to the transactivation domain of BZLF1. Although a functional relationship between BZLF1 and PKC could be mediated by RACKs, RACK1 did not have a detectable effect on the phosphorylation status of BZLF1 in in vitro or in vivo phosphorylation assays. We suggest that RACK1 may act as a scaffolding protein on BZLF1 independently of activated PKCs.
Asunto(s)
Proteínas de Unión al ADN/metabolismo , Péptidos/metabolismo , Proteína Quinasa C/metabolismo , Transactivadores/metabolismo , Proteínas Virales/metabolismo , Secuencia de Aminoácidos , Núcleo Celular/metabolismo , Células Cultivadas , Proteínas de Unión al ADN/genética , Humanos , Datos de Secuencia Molecular , Fosforilación , Receptores de Cinasa C Activada , Transactivadores/genética , Transcripción Genética , Técnicas del Sistema de Dos HíbridosRESUMEN
The propagation of herpesviruses has long been viewed as a temporally regulated sequential process that results from the consecutive expression of specific viral transactivators. As a key step in this process, lytic viral DNA replication is considered as a checkpoint that controls the expression of the late structural viral genes. In a novel genetic approach, we show that both hypotheses do not hold true for the Epstein-Barr virus (EBV). The study of viral mutants of EBV in which the early genes BZLF1 and BRLF1 are deleted allowed a precise assignment of the function of these proteins. Both transactivators were absolutely essential for viral DNA replication. Both BZLF1 and BRLF1 were required for full expression of the EBV proteins expressed during the lytic program, although the respective influence of these molecules on the expression of various viral target genes varied greatly. In replication-defective viral mutants, neither early gene expression nor DNA replication was a prerequisite for late gene expression. This work shows that BRLF1 and BZLF1 harbor distinct but complementary functions that influence all stages of viral production.
Asunto(s)
Proteínas de Unión al ADN/metabolismo , Herpesvirus Humano 4/genética , Proteínas Inmediatas-Precoces/metabolismo , Transactivadores/metabolismo , Proteínas Virales/metabolismo , Línea Celular , Replicación del ADN , ADN Viral/biosíntesis , Proteínas de Unión al ADN/genética , Células Epiteliales/virología , Regulación Viral de la Expresión Génica , Proteínas Inmediatas-Precoces/genética , Mutación , Proteínas Recombinantes/metabolismo , Transactivadores/genética , Proteínas de la Matriz Viral/biosíntesis , Proteínas Virales/genéticaRESUMEN
Most human herpesviruses are ubiquitous and are closely associated with a number of severe acute infections and human tumors. Progress in herpesvirus genetics has made members of the herpesvirus family accessible, such that they have become more attractive as gene vectors to be used in the treatment of various diseases, including the prevention of herpesvirus-related afflictions. This review summarizes recent progress and provides a basis for development of new viral and therapeutic strategies.
Asunto(s)
Vectores Genéticos , Herpesviridae/genética , Animales , Terapia Genética/efectos adversos , Terapia Genética/métodos , Herpesviridae/fisiología , Humanos , Neoplasias/terapia , Seguridad , Replicación ViralRESUMEN
DNA replication of Epstein-Barr virus (EBV) during the productive phase of the life cycle of this herpesvirus depends on the cis-acting element oriLyt. It consists of two essential domains, the upstream and the downstream component. Whereas the upstream component contains several DNA-binding motifs for the viral activator protein BZLF1, the downstream component is known to be the binding site of several cellular proteins. We identified cellular transcription factors that bind synergistically to a functionally relevant subsequence of the downstream component, the TD element. Two of these transcription factors, ZBP-89 and Sp1, stimulate replication as shown by protein fusions with the GAL4 DNA-binding domain and a single GAL4 DNA-binding motif inserted into the TD element. In protein binding assays, we observed an interaction of Sp1 and ZBP-89 with the viral DNA polymerase and its processivity factor. Our data indicate that cellular transcriptional activators tether viral replication proteins to the lytic origin via direct protein-protein interactions to assemble the viral replication complex at oriLyt.
Asunto(s)
Replicación del ADN/genética , Herpesvirus Humano 4/genética , Origen de Réplica/genética , Proteínas de Saccharomyces cerevisiae , Proteínas Virales/metabolismo , Secuencia de Bases , Proteínas de Unión al ADN/análisis , Proteínas de Unión al ADN/genética , Proteínas de Unión al ADN/metabolismo , Proteínas Fúngicas/genética , Datos de Secuencia Molecular , Proteínas Recombinantes de Fusión/genética , Saccharomyces cerevisiae/genética , Factor de Transcripción Sp1/metabolismo , Transactivadores/genética , Factores de Transcripción/genética , Factores de Transcripción/metabolismoRESUMEN
Latent membrane protein 1 (LMP1) acts like a permanently activated receptor of the tumor necrosis factor (TNF)-receptor superfamily and is absolutely required for B cell immortalization by Epstein-Barr virus. Molecular and biochemical approaches demonstrated that LMP1 usurps cellular signaling pathways resulting in the induction of NF-kappaB and AP-1 via two C-terminal activating regions. We demonstrate here that a third region encompassing a proline rich sequence within the 33 bp repetitive stretch of LMP1's C-terminus is required for the activation of Janus kinase 3 (JAK3). The interaction of LMP1 and JAK3 leads to the enhanced tyrosine auto/transphosphorylation of JAK3 within minutes after crosslinking of a conditional NGF-R:LMP1 chimera and is a prerequisite for the activation of STAT transcription factors. These results reveal a novel activating region in the LMP1 C-terminus and identify the JAK/STAT pathway as a target of this viral integral membrane protein in B cells.
Asunto(s)
Proteínas de Unión al ADN/metabolismo , Herpesvirus Humano 4/metabolismo , Proteínas Tirosina Quinasas/metabolismo , Transducción de Señal , Transactivadores/metabolismo , Proteínas de la Matriz Viral/metabolismo , Secuencia de Aminoácidos , Animales , Linfocitos B/enzimología , Linfocitos B/metabolismo , Línea Celular , Secuencia de Consenso/genética , ADN/genética , ADN/metabolismo , Proteínas de Unión al ADN/genética , Activación Enzimática , Herpesvirus Humano 4/genética , Humanos , Janus Quinasa 3 , Ratones , Datos de Secuencia Molecular , Fosforilación , Fosfotirosina/metabolismo , Prolina/genética , Prolina/metabolismo , Unión Proteica , Proteínas Tirosina Quinasas/genética , Receptores de Factor de Crecimiento Nervioso/genética , Receptores de Factor de Crecimiento Nervioso/metabolismo , Proteínas Recombinantes de Fusión/genética , Proteínas Recombinantes de Fusión/metabolismo , Secuencias Repetitivas de Aminoácido , Factor de Transcripción STAT1 , Eliminación de Secuencia , Transactivadores/genética , Proteínas de la Matriz Viral/química , Proteínas de la Matriz Viral/genéticaRESUMEN
The Epstein-Barr virus latent membrane protein 1 (LMP1) binds tumor necrosis factor receptor (TNFR)-associated factors (TRAFs) and the TNFR-associated death domain protein (TRADD). Moreover, it induces NF-kappaB and the c-Jun N-terminal kinase 1 (JNK1) pathway. Thus, LMP1 appears to mimick the molecular functions of TNFR1. However, TNFR1 elicits a wide range of cellular responses including apoptosis, whereas LMP1 constitutes a transforming protein. Here we mapped the JNK1 activator region (JAR) of the LMP1 molecule. JAR overlaps with the TRADD-binding domain of LMP1. In contrast to TNFR1, LMP1 recruits TRADD via the TRADD N-terminus but not the TRADD death domain. Consequently, the molecular function of TRADD in LMP1 signaling differs from its role in TNFR1 signal transduction. Whereas NF-kappaB activation by LMP1 was blocked by a dominant-negative TRADD mutant, LMP1 induces JNK1 independently of the TRADD death domain and TRAF2, which binds to TRADD. Further downstream, JNK1 activation by TNFR1 involves Cdc42, whereas LMP1 signaling to JNK1 is independent of p21 Rho-like GTPases. Although both LMP1 and TNFR1 interact with TRADD and TRAF2, the different topologies of the signaling complexes correlate with substantial differences between LMP1 and TNFR1 signal transduction to JNK1.
Asunto(s)
Antígenos CD/metabolismo , Proteínas Quinasas Dependientes de Calcio-Calmodulina/metabolismo , Proteínas Quinasas Activadas por Mitógenos , Proteínas Oncogénicas Virales/metabolismo , Proteínas/metabolismo , Receptores del Factor de Necrosis Tumoral/metabolismo , Proteínas de la Matriz Viral/metabolismo , Sitios de Unión , Transformación Celular Neoplásica , Activación Enzimática , GTP Fosfohidrolasas/metabolismo , Proteínas de Unión al GTP/metabolismo , Humanos , Proteínas Quinasas JNK Activadas por Mitógenos , Modelos Biológicos , Modelos Moleculares , Mutación , FN-kappa B/metabolismo , Unión Proteica , Proteínas/genética , Receptores Tipo I de Factores de Necrosis Tumoral , Transducción de Señal , Factor 1 Asociado a Receptor de TNF , Factor 2 Asociado a Receptor de TNF , Proteínas de Unión al GTP rhoRESUMEN
On the basis of the B lymphotropic Epstein-Barr virus (EBV), we have constructed a virus-free packaging cell line that allows encapsidation of plasmids into herpesvirus particles. This cell line harbors an EBV mutant whose packaging signals have been deleted. The gene vectors, which can encompass very large, contiguous pieces of foreign DNA, carry all cis-acting elements involved in amplification and encapsidation into virus-like particles as well as those essential for extrachromosomal maintenance in the recipient cell. Although this first-generation packaging cell line suffers from unwanted recombination between the helper virus genome and gene vector DNAs, this approach opens the way to delivery and stable maintenance of any transgene in human B cells.